Kang Litai Pharmaceutical

Zhuhai Kanglitai Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and industrialization of recombinant protein drugs. Founded in 2014, the company has established a robust platform for cytokine-based immunotherapies, with a primary focus on oncology and infectious diseases. Its lead candidate, KLT-101 (recombinant human interleukin-12), is currently in Phase 2 clinical trials for indications including radiation-induced hematopoietic damage and chronic hepatitis B. Beyond IL-12, Kanglitai is advancing a pipeline of long-acting cytokines and multi-functional fusion proteins. The company operates integrated R&D and GMP-compliant manufacturing facilities in Zhuhai. By leveraging its expertise in protein engineering, Kanglitai aims to provide innovative solutions for patients with limited treatment options.